PD‐L1 and PD‐L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma
| Autor: | Kazuo Okadome, Noriko Yasuda-Yoshihara, Taisuke Yagi, Tasuku Toihata, Takatsugu Ishimoto, Masayuki Watanabe, Yoshifumi Baba, Daichi Nomoto, Hiroshi Sawayama, Naoya Yoshida, Katsuhiro Ogawa, Masaaki Iwatsuki, Shiro Iwagami, Yuji Miyamoto, Yoshihiro Komohara, Hideo Baba |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
Esophageal Neoplasms medicine.medical_treatment B7-H1 Antigen Metastasis Cell Line Tumor PD-L1 Biomarkers Tumor medicine Humans Lymph node Cisplatin Chemotherapy biology business.industry General Medicine Esophageal cancer Programmed Cell Death 1 Ligand 2 Protein medicine.disease Neoadjuvant Therapy medicine.anatomical_structure Oncology Fluorouracil Lymphatic Metastasis Cancer research biology.protein Biomarker (medicine) Esophageal Squamous Cell Carcinoma Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Cancer Science. 113:399-410 |
| ISSN: | 1349-7006 1347-9032 |
| DOI: | 10.1111/cas.15198 |
| Popis: | Immune checkpoint inhibitors have shown efficacy in various cancers. Although programmed death ligand 1/2 (PD-L1/L2) expressions have been demonstrated as predictive biomarkers of response to immune checkpoint inhibitors and prognostic markers, whether PD-L1/L2 expression is altered in esophageal squamous cell carcinoma during the therapeutic course is unclear. Whether PD-L1/L2 expression in metastatic or recurrent lesions is consistent with that in primary tumors is also unknown. This study included 561 surgically resected esophageal squamous cell carcinomas and PD-L1/L2 expression was evaluated by immunohistochemistry. We investigated the influence of chemotherapeutic drugs (cisplatin and fluorouracil) on PD-L1/L2 expression and PD-L1/L2-related pathways in vitro. We also examined PD-L1/L2 expression in 18 surgically resected lymph node metastases and 10 recurrent lesions compared with primary lesions. The positive rate of PD-L1 was significantly higher in patients with preoperative chemotherapy than in those without preoperative therapy. The positive rate of PD-L2 expression showed no significant difference between patient groups. Cisplatin increased PD-L1 expression in cancer cell lines in vitro, but decreased PD-L2 in some cell lines. The effects of cisplatin on phosphorylated signal transducer and activator of transcription 1/3 (pSTAT1/3) also differed depending on cell lines. Fluorouracil increased PD-L1 and PD-L2 expression. PD-L1/L2 expression in lymph node metastases and recurrent lesions did not always match expression in primary lesions. PD-L1/L2 expression may be altered by preoperative chemotherapy, and PD-L1 /L2 expression in primary lesions does not always match that of metastatic/recurrent lesions. Thus, one-time evaluation is not sufficient to evaluate PD-L1/L2 expression as a biomarker in esophageal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text